Edwards Lifesciences stock holds above $90 as Q2 2026 growth beats forecasts
Published on 08/26/2026 at 21:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences (ISIN US28176E1082) stock is trading close to the low $90s in late August 2026 after the company delivered double-digit second-quarter revenue growth and earnings per share ahead of market forecasts, supported by ongoing demand for its structural heart therapies.
Per compiled market data as of August 24, 2026, the shares closed at $90.50, leaving a gap of less than $6 to a one-year high of $96.29 and sitting below an average analyst price target above $100, signaling that the market still prices in further growth potential this stock summary.
In Q2 2026, which ended on June 30, 2026, Edwards Lifesciences generated revenue of $1.74 billion, an increase of 13.6 percent compared with the same quarter a year earlier, highlighting robust momentum in its core structural heart and critical care businesses a detailed performance review.
The company reported earnings per share of $0.78 in that same quarter, exceeding a consensus estimate of $0.74 by $0.04 and underscoring managements focus on profitability alongside revenue growth an earnings-focused overview.
Compared with the prior-year period, when earnings per share stood at $0.67, the latest $0.78 figure represents an increase of $0.11, illustrating how topline expansion and margin discipline combined to lift bottom-line performance over a 12-month span a year-on-year comparison.
Institutional demand and analyst consensus
Recent regulatory filings compiled on August 26, 2026, show that multiple institutional investors have been adjusting their positions in Edwards Lifesciences, with some funds initiating new stakes and others adding shares, contributing to a diversified base of long-term holders a news overview.
One such filing notes that an investor acquired 4,301,222 shares valued at $389,089,000, underlining how large-scale allocations can reinforce liquidity and signal confidence in the companys trajectory for structural heart and critical care solutions a filing summary.
Across the analyst community, a compiled overview indicates a consensus rating in the Moderate Buy range, with an average price target of $100.27, placing the target roughly $9.77 above the August 24, 2026 closing price of $90.50 and suggesting upside potential if the company delivers on its guidance a consensus snapshot.
Recent commentary also notes that individual price targets have been set in a range from $105 to $110, which, compared with the current share price region in the low $90s, would imply potential gains of more than 10 percent if those views are realized, though short-term volatility remains possible a price-target overview.
Guidance and valuation context
In its July 23, 2026 update for Q2 2026, Edwards Lifesciences reiterated a focus on profitable growth and set guidance for Q3 2026 earnings per share in a range from $0.71 to $0.77, framing investors expectations for the next reporting period a guidance recap.
For the full year 2026, management currently projects earnings per share between $2.95 and $3.05, and if results were to land at the top of that range, the August 24, 2026 closing price of $90.50 would equate to a forward price-to-earnings multiple in the low 30s, a valuation level that aligns with expectations for sustained growth in a specialized medical device franchise a valuation-focused summary.
The same guidance framework provides investors with a quantitative roadmap, as meeting the midpoint of the $2.95 to $3.05 range would represent a step up from historical earnings and help validate the premium multiple that the market currently assigns to the stock an earnings-guidance report.
From a revenue perspective, the Q2 2026 growth rate of 13.6 percent year over year compares favorably with many diversified medtech peers, and within that topline figure, structural heart therapies and newer transcatheter programs have acted as the primary engines of expansion an article on revenue drivers.
In addition, company commentary highlighted that in Q2 2026 the transcatheter mitral and tricuspid therapies segment recorded revenue of $195.9 million, an increase of 47.3 percent versus the prior-year quarter, underscoring how newer therapies in the portfolio contribute a growing share of overall sales a segment-growth summary.
Margins and operational performance
Profitability metrics from the Q2 2026 report show that Edwards Lifesciences maintained a gross margin of 77.5 percent on a reported basis and 77.6 percent on an adjusted basis, essentially flat compared with the prior-year period as lower manufacturing costs offset foreign-exchange headwinds a margin performance review.
Operating margin for the quarter came in at 29.5 percent on a reported basis and 30.0 percent on an adjusted basis, reinforcing the companys capacity to invest in research and development and commercial expansion while still delivering attractive returns on capital an operating-margin summary.
Separate analysis of the same period notes that net margin stood at 15.43 percent and return on equity reached 15.68 percent, while revenue was up 13.6 percent year over year, providing a comprehensive view of how top-line growth translates into shareholder-focused profitability metrics a profitability overview.
Taken together, these figures suggest that Edwards Lifesciences is managing to grow its transcatheter therapies and structural heart portfolio without eroding its historically high gross margins, a balancing act that can support continued investment in innovation while sustaining an earnings profile that supports its market valuation a balanced-growth commentary.
Product focus on transcatheter heart valves
One of the most important contributors to Edwards Lifesciences growth is its portfolio of transcatheter heart valves, which enable minimally invasive replacement or repair of diseased heart valves without the need for open-heart surgery, addressing conditions such as severe aortic stenosis and mitral regurgitation through catheter-based approaches.
In Q2 2026, company disclosures noted that transcatheter aortic valve replacement procedures helped push the broader transcatheter franchise above the $1.3 billion revenue mark within the quarter, reflecting continued uptake among patients and clinicians who value shorter hospital stays and faster recovery times compared with traditional surgery a transcatheter revenue note.
Alongside the established aortic valve business, the transcatheter mitral and tricuspid therapies segment delivered revenue of $195.9 million in Q2 2026, and its 47.3 percent year-over-year growth rate indicates that emerging indications and new geographies are accelerating adoption, adding another growth vector beyond the core aortic offering a mitral and tricuspid segment overview.
These therapies are complemented by critical care monitoring technologies that provide real-time hemodynamic data during complex procedures and in intensive care settings, giving clinicians additional tools to optimize patient outcomes and broadening the companys addressable market in hospitals worldwide a news item on growth drivers.
Stock performance and trading context
Historical price data compiled for Edwards Lifesciences show that on August 24, 2026, the shares opened at $89.89, traded within an intraday range from $89.46 to $91.11, and closed at $90.50, marking a daily gain of 0.79 percent on volume of 2.72 million shares a historical price snapshot.
The same price history lists a one-year high of $96.29, which means that the August 24, 2026 closing level of $90.50 left the stock 6.0 percent below that high, a margin that some investors may interpret as headroom for further gains if the company continues to execute on its growth initiatives a 52-week-high comparison.
On August 26, 2026, several compiled quote overviews indicated that Edwards Lifesciences shares opened trading at $90.92 on the New York Stock Exchange, with descriptions noting that the opening level was close to the upper end of the stocks 12-month range, reflecting continued investor interest following the Q2 2026 results and ongoing institutional activity a quote-focused note.
Another summary of trading conditions describes Edwards Lifesciences stock as being up 0.5 percent in recent sessions, with the $90.92 opening price on August 26, 2026, positioning the shares close to the upper part of their 12-month band and consistent with the pattern of modest gains that followed the July 23, 2026 earnings release a mention of recent stock movement.
For valuation-focused investors, the combination of a recent closing price of $90.50, a full-year 2026 earnings guidance range topping out at $3.05 per share, and a consensus price target of $100.27 provides a framework for assessing how much of the anticipated earnings trajectory is already reflected in the shares and how much is priced in as future growth a valuation framework discussion.
Representative product in structural heart care
A representative example from Edwards Lifesciences portfolio is its family of transcatheter aortic valve replacement systems, designed to treat patients with severe aortic stenosis who are at elevated risk for conventional open-heart surgery, by delivering a replacement valve via catheter through a small incision in the femoral artery.
These systems have become central to modern structural heart care because they can reduce hospital stays, lower complication rates in selected patients, and expand treatment options to older or more fragile individuals, and the company continues to refine valve designs and delivery catheters to improve performance, durability, and ease of use in cath labs and hybrid operating rooms worldwide.
Edwards Lifesciences stock on the NYSE
Edwards Lifesciences stock trades on the New York Stock Exchange under the ticker EW, and a compiled data set shows that it last closed at $90.50 on August 24, 2026, at 4:00 p.m. ET, in US trading, reflecting modest gains in the sessions following the Q2 2026 earnings release and guidance update a closing-price record.
Fact box
Company: Edwards Lifesciences Corp.
ISIN: US28176E1082
Ticker: EW
Exchange: NYSE
Price (as of August 24, 2026, 4:00 p.m. ET): $90.50 USD
Market cap: $55.0 billion (as of August 24, 2026)
Sector / Industry: Health care / Medical devices
Index membership: S&P 500
